This site is fictional demo content. It is not real news or affiliated with any real organization. Do not treat it as fact or professional advice.

NextPaper Logo
nextpaper.ccCYBER CHRONICLE
RSS
EN中文

Full article

FULL TEXT

View this issue
BriefMEDTECH

Smart Insulin Patch InsulPatch Completes Human Trials: Ending Daily Injections for Diabetics

InsulPatch, jointly developed by Swiss pharma Roche and the University of Padua in Italy, is a smart insulin patch worn on the skin. The patch automatically releases insulin based on blood glucose levels, and clinical trials showed a 28 percent improvement in HbA1c markers.

InsulPatch, the smart insulin patch developed jointly by Swiss pharma Roche and the University of Padua in Italy, has completed key human trials. The skin-worn patch automatically releases insulin based on blood glucose levels, freeing diabetics from multiple daily injections.

At the heart of InsulPatch is a microneedle array sensitive to glucose concentration. The patch is made up of hundreds of tiny needles, each storing a small amount of insulin. The needles are coated with a special polymer that swells and releases insulin when blood glucose rises.

The clinical trial was conducted at five hospitals in Italy and Germany and enrolled 120 patients with type 2 diabetes. Over twelve months, patients using InsulPatch showed an average 28 percent improvement in HbA1c, equivalent to moving up one clinical grade in diabetes control.

Roche Chief Medical Officer Levi Garraway said InsulPatch represents a paradigm shift in diabetes management. The company plans to submit marketing applications to the FDA and EMA in the second half of 2026 and expects approval in 2027, with initial launches in the United States and European Union.